|June 4, 2014|
|07:39 EDT||AGN||Allergan management to meet with UBS|
Meetings to be held in Copenhagen/Paris on June 4 hosted by UBS.
News For AGN From The Last 14 Days
|September 2, 2015|
|07:17 EDT||AGN||Allergan announces FDA approval of updated label for TEFLARO|
Subscribe for More Information
|07:09 EDT||AGN||Allergan announces topline results from RECAPTURE 1 and 2|
Allergan announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ as a treatment for adult hospitalized patients with complicated urinary tract infections, including pyelonephritis. AVYCAZ consists of a cephalosporin, ceftazidime, an established treatment for serious bacterial infections, and the first and only non-beta lactam beta-lactamase inhibitor, avibactam. The addition of avibactam protects ceftazidime from being broken down by certain beta-lactamases that are produced by these resistant bacteria. The global RECAPTURE 1 and 2 Phase III studies evaluated the safety and efficacy of AVYCAZ administered intravenously as a two-hour infusion, compared to doripenem, administered intravenously as a 30-minute infusion, in hospitalized adult patients with cUTI, including pyelonephritis. Data from the studies were analysed as a single-pooled dataset with the agreement of the US FDA and the EMA. AVYCAZ was also effective in treating cUTI patients infected with ceftazidime-resistant bacteria. Allergan plans to submit this data as a supplemental New Drug Application (sNDA) to the Food and Drug Administration by the end of 2015.
|August 31, 2015|
|08:04 EDT||AGN||Allergan completes Nuarex acquisition|
Subscribe for More Information
|07:39 EDT||AGN||Citi calls Allergan a 'stock to own,' keeps $360 target|
Citi analyst Liav Abraham calls Allergan a "stock to own" given its "attractive" organic growth profile, pipeline potential and ability to do more acquisitions. He reiterates a Buy rating on the stock with a $360 price target.
|August 28, 2015|
|09:50 EDT||AGN||Allergan plans for generic version of Endo's Fortesta blocked, Bloomberg reports|
A judge upheld Endo's (ENDP) patents on Fortesta expiring in 2018 and blocked Allergan's (AGN) bid to launch a generic version of the testosterone gel, according to Bloomberg.
|August 25, 2015|
|08:14 EDT||AGN||Allergan multiple is low, says Leerink|
Leerink predicts that Allergan's 2016 EPS will come in at $17-$18. The firm thinks the company has "durable revenue streams," and a "deep pipeline with several potential blockbuster candidates." Leerink adds that the company "has significant capacity for M&A." It keeps a $388 price target and Outperform rating on the shares.
|August 24, 2015|
|08:37 EDT||AGN||Allergan recalls certain lots of REFRESH, FML, Blephamide treatments|
Allergan announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH Lacri-Lube 3.5g and 7g for dry eye, REFRESH P.M. 3.5g for dry eye, FML 0.1%, and Blephamide 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.
|August 20, 2015|
|08:16 EDT||AGN||Allergan's Botox resubmission for lower limb spasticiy accepted by FDA|
Allergan 's resubmission of its Supplemental Biologics License Application for Botox for the treatment of adults with lower limb spasticity in adults has been accepted by the FDA. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act date is expected to be in 1Q16. The resubmission provides additional data from a double-blind, placebo controlled study involving 468 patients with lower limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.